Drug profile · INN
phenylbutazone
AZOLID
phenylbutazone (AZOLID) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — phenylbutazone
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 0
- Data quality
- 0.84
Quick answer
phenylbutazone (AZOLID) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase inhibitor
Primary target: Cyclooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
-
US 11542275
Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors
granted -
US 11365205
Imidazolidin-2-one compounds as PRMT5 modulators
granted -
US 10709692
Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
granted -
US 10544113
Thiazolidinone compounds and use thereof
granted -
US 9060941
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
granted -
US 8637560
Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
granted -
US 8404650
Methods of treating cancer with doxazolidine and prodrugs thereof
granted -
US 8283370
Imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use
granted -
US 8084058
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
granted -
US 7998992
Oxazolidinone derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1
granted -
US 7632841
2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
granted -
EP 2061775
SPIRO-OXAZOLIDINON-VERBINDUNGEN UND IHRE VERWENDUNG ALS VERSTÄRKER METABOTROPER GLUTAMATREZEPTOREN
granted -
US 7528133
Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
granted -
US 7435741
2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
granted -
US 7300928
Benzimidazolidinone derivatives as muscarinic agents
granted -
US 7291611
Benzimidazolidinone derivatives as muscarinic agents
granted -
US 7273857
Benzimidazolidinone derivatives as muscarinic agents
granted -
US 7087593
Benzimidazolidinone derivatives as muscarinic agents
granted -
US 6951849
Benzimidazolidinone derivatives as muscarinic agents
expired -
US 6552058
Oxazolidinedione derivatives and their use
expired
Frequently asked questions
What is phenylbutazone?
phenylbutazone (AZOLID) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for phenylbutazone?
AZOLID is a marketed brand name for phenylbutazone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of phenylbutazone?
phenylbutazone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.